Header Logo

Connection

Alan Landay to Acquired Immunodeficiency Syndrome

Back to Details
This is a "connection" page, showing publications Alan Landay has written about Acquired Immunodeficiency Syndrome.
Alan Landay
Connection Strength
2.316
Acquired Immunodeficiency Syndrome
  1. Dysregulated B-cell TLR2 expression and elevated regulatory B-cell frequency precede the diagnosis of AIDS-related non-Hodgkin lymphoma. AIDS. 2015 Aug 24; 29(13):1659-64.
    View in: PubMed
    Score: 0.493
  2. Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. Clin Diagn Lab Immunol. 2000 May; 7(3):352-9.
    View in: PubMed
    Score: 0.171
  3. Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities. Curr HIV/AIDS Rep. 2015 Mar; 12(1):54-67.
    View in: PubMed
    Score: 0.119
  4. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1184-95.
    View in: PubMed
    Score: 0.097
  5. The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr HIV Res. 2012 Apr; 10(3):202-10.
    View in: PubMed
    Score: 0.097
  6. Isolation of HIV-1 from monocytes of individuals negative by conventional culture. J Infect Dis. 1990 Apr; 161(4):706-10.
    View in: PubMed
    Score: 0.085
  7. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis. 2010 Mar 15; 201(6):823-34.
    View in: PubMed
    Score: 0.085
  8. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010 Feb; 7(1):4-10.
    View in: PubMed
    Score: 0.084
  9. Precision and accuracy of absolute lymphocyte counts. Clin Immunol Immunopathol. 1989 Jul; 52(1):19-27.
    View in: PubMed
    Score: 0.080
  10. Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9.
    View in: PubMed
    Score: 0.078
  11. Diagnosis of human immunodeficiency virus infection in seronegative homosexuals presenting with an acute viral syndrome. JAMA. 1987 Sep 04; 258(9):1196-9.
    View in: PubMed
    Score: 0.071
  12. Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol. 1987 Aug; 22(4):357-63.
    View in: PubMed
    Score: 0.070
  13. Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 Aug 15; 37(4):551-8.
    View in: PubMed
    Score: 0.053
  14. Immunologic studies in asymptomatic hemophilia patients. Relationship to acquired immune deficiency syndrome (AIDS). J Clin Invest. 1983 May; 71(5):1500-4.
    View in: PubMed
    Score: 0.052
  15. Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):56-62.
    View in: PubMed
    Score: 0.050
  16. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1--infected women. J Infect Dis. 2002 Feb 15; 185(4):439-47.
    View in: PubMed
    Score: 0.048
  17. Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy. AIDS. 2021 12 01; 35(15):2489-2495.
    View in: PubMed
    Score: 0.048
  18. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr. 2000 Dec 01; 25(4):289-95.
    View in: PubMed
    Score: 0.044
  19. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS. 2000 Jan 07; 14(1):11-21.
    View in: PubMed
    Score: 0.042
  20. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis. 1999 Apr; 179(4):799-807.
    View in: PubMed
    Score: 0.040
  21. Hepatitis G virus RNA is common in AIDS patients' plasma but is not associated with abnormal liver function tests or other clinical syndromes. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 01; 19(4):408-12.
    View in: PubMed
    Score: 0.039
  22. High prevalence of hepatitis G virus RNA and antibody to probable viral envelope protein but not both in AIDS patients' plasma. AIDS. 1998 Mar 26; 12(5):530-1.
    View in: PubMed
    Score: 0.037
  23. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis. 1997 May; 24(5):764-74.
    View in: PubMed
    Score: 0.035
  24. Effect of zidovudine therapy on CD8+ T cell anti-HIV activity. Clin Immunol Immunopathol. 1994 Oct; 73(1):80-7.
    View in: PubMed
    Score: 0.029
  25. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol. 1993 Oct; 69(1):106-16.
    View in: PubMed
    Score: 0.027
  26. Postmortem recovery of human immunodeficiency virus type 1 from plasma and mononuclear cells. Implications for occupational exposure. Arch Pathol Lab Med. 1992 Nov; 116(11):1124-7.
    View in: PubMed
    Score: 0.025
  27. Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients. J Infect Dis. 1992 Oct; 166(4):723-30.
    View in: PubMed
    Score: 0.025
  28. Multiple patterns of alloantigen presenting/stimulating cell dysfunction in patients with AIDS. J Immunol. 1991 Apr 01; 146(7):2207-13.
    View in: PubMed
    Score: 0.023
  29. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals. AIDS. 1991 Mar; 5(3):289-93.
    View in: PubMed
    Score: 0.023
  30. Analysis of lymphocytes, monocytes, and neutrophils from human immunodeficiency virus (HIV)-infected persons for HIV DNA. J Infect Dis. 1990 Dec; 162(6):1239-44.
    View in: PubMed
    Score: 0.022
  31. Application of flow cytometry to the study of HIV infection. AIDS. 1990 Jun; 4(6):479-97.
    View in: PubMed
    Score: 0.021
  32. Results of the flow cytometry ACTG quality control program: analysis and findings. Clin Immunol Immunopathol. 1989 Jul; 52(1):68-84.
    View in: PubMed
    Score: 0.020
  33. Treatment of human immunodeficiency virus-related thrombocytopenia with zidovudine. JAMA. 1988 Nov 25; 260(20):3045-8.
    View in: PubMed
    Score: 0.019
  34. Rapid rebound of serum human immunodeficiency virus antigen after discontinuing zidovudine therapy. J Infect Dis. 1988 Nov; 158(5):1132-3.
    View in: PubMed
    Score: 0.019
  35. HIV isolation from plasma of HIV-infected persons. N Engl J Med. 1987 Jun 11; 316(24):1547-8.
    View in: PubMed
    Score: 0.017
  36. Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr. 2003 Aug 01; 33(4):448-60.
    View in: PubMed
    Score: 0.013
  37. Acquired immunodeficiency syndrome with Pneumocystis carinii pneumonia and Mycobacterium avium-intracellulare infection in a previously healthy patient with classic hemophilia. Clinical, immunologic, and virologic findings. Ann Intern Med. 1983 Mar; 98(3):287-90.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.